Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
The agreement with Mexico's agriculture department covers studies to evaluate molecular detection assays for bovine TB, as well as studies on zoonotic TB diagnosis.
In Genome Biology this week: Mycobacterium tuberculosis population dynamics, mapping precision in GWAS, and more.
The partners aim to sequence thousands of tuberculosis bacteria isolates as part of a broader effort to develop personalized treatments for the disease.
The Alabama-based firm has grown its infectious disease testing menu for the BD Max system to six CE-marked tests identifying bacteria, viruses, or fungi.
The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.
Researchers sequenced and analyzed 169 Mycobacterium tuberculosis strains from people with and without HIV infections.
In Nucleic Acids Research this week: isomiR-based cancer classifier, map of VjbR binding in Brucella, and more.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.